How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tisotumab vedotin

Marketing authorisation indication

2.1

Tisotumab vedotin (Tivdak, Genmab) is indicated for 'the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy'.

Price

2.3

The list price for tisotumab vedotin has not yet been approved. The company have provided an anticipated list price, which is considered confidential until it has been approved.

2.4

The company has a commercial arrangement, which would have applied if tisotumab vedotin had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Genmab will be included here when guidance is published.